Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by bligickaon Jan 30, 2021 12:43pm
86 Views
Post# 32428513

RE:RE:RE:C'mon man

RE:RE:RE:C'mon manBased on the capital needed to complete Phase 3, I would say a goverment grant is the best alternative ......If they raised it doning .075 pp's shareholder dilution would be out of this world and the stock would never appreciate .....careful what you wish for !!!

Doing a licensing deal with a Country in exchange for finishing phase 3 trials would be a win win !!! They could still sell or license to the rest of the world !!!




silentrunning wrote: PP is perhaps the wisest move, would ensure independence of the corporate entity. Not trying to 2nd guess mgmt nor undermine efforts.... Interesting position to be in though don't you think, being in the enviable position of having Pfizer or/& Astrazeneca as our potential benefactors/partners/parent's . VXL could hold the IP/science which may be the key to unlock vaccine, cancer, Alzheimer's?? In any event, one wouldn't think they'd allow an association with just anyone. Prearranged marriage?? Perhaps a bunch of bunk, or quite possibly one of a myriad of possible scenarios?? best all
Vikingstock wrote: A PP or joint venture may be needed to move forward from the lab. Question is, a pp at what price...... Reflecting significant progress made...




<< Previous
Bullboard Posts
Next >>